Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study-Reference-Cited by-同舟云学术

Burden of Migraine in Patients With Preventive Treatment Failure Attending European Headache Specialist Centers: Real-World Evidence From the BECOME Study

Published:2021-10-13 Issue:2 Volume:10 Page:1691-1708
ISSN:2193-8237
Container-title:Pain and Therapy
language:en
Short-container-title:Pain Ther

Author:

Pozo-Rosich Patricia,Lucas Christian,Watson David P. B.,Gaul Charly,Ramsden Emma,Ritter Shannon,Martelletti Paolo,Snellman Josefin

Funder

Novartis

Publisher

Springer Science and Business Media LLC

Subject

Anesthesiology and Pain Medicine,Neurology (clinical)

Link

https://link.springer.com/content/pdf/10.1007/s40122-021-00331-3.pdf

Reference16 articles.

1. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211–59.

2. Steiner TJ, Stovner LJ, Vos T, Jensen R, Katsarava Z. Migraine is first cause of disability in under 50s: will health politicians now take notice? J Headache Pain. 2018;19(1):17.

3. Lipton RB, Bigal ME, Diamond M, et al. Migraine prevalence, disease burden, and the need for preventive therapy. Neurology. 2007;68(5):343–9.

4. Adams AM, Serrano D, Buse DC, et al. The impact of chronic migraine: the Chronic Migraine Epidemiology and Outcomes (CaMEO) Study methods and baseline results. Cephalalgia. 2015;35(7):563–78.

5. Blumenfeld AM, Varon SF, Wilcox TK, et al. Disability, HRQoL and resource use among chronic and episodic migraineurs: results from the International Burden of Migraine Study (IBMS). Cephalalgia. 2011;31(3):301–15.

Cited by 21 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Cost per treatment responder analysis of atogepant compared to rimegepant for the preventive treatment of episodic migraine;Headache: The Journal of Head and Face Pain;2024-09-09

2. Early Use of Erenumab vs Nonspecific Oral Migraine Preventives;JAMA Neurology;2024-05-01

3. Refractory migraine;Neurology, Neuropsychiatry, Psychosomatics;2024-04-24

4. Migraine treatment: quo vadis? Real-world data study (2015–2022) in Spain;BMC Neurology;2024-04-02

5. Safety and efficacy of atogepant for the preventive treatment of episodic migraine in adults for whom conventional oral preventive treatments have failed (ELEVATE): a randomised, placebo-controlled, phase 3b trial;The Lancet Neurology;2024-04